Match Group Inc (MTCH) Stock Price Today
Poolbeg Pharma funds trials through 2028, advancing cancer and obesity drug studies.
Poolbeg Pharma has secured funding to complete its clinical trials through to the second quarter of 2028. The company is currently recruiting patients for its TOPICAL trial of POLB 001, a drug aimed at preventing cytokine release syndrome in cancer p...
Genflow Biosciences to reveal dog longevity trial results and advance glaucoma and liver disease programs
Genflow Biosciences will present full results from its canine ageing trial at the Animal Longevity Summit in Toronto, highlighting the safety and potential health benefits of its GF-1004 treatment aimed at slowing ageing. The company is also progress...
Telo Genomics reports promising blood test results for detecting residual multiple myeloma cells, aiming for 2027 commercialization.
Telo Genomics announced new clinical research showing its blood-based TELO-MRD test detects residual multiple myeloma cells more sensitively than traditional bone marrow tests like Adaptive clonoSEQ. The TELO-MRD liquid biopsy identifies circulating ...
Nvidia launches AI safety platform amid rising concerns over AI risks and OpenAI halts GPT-6.1 release.
Nvidia introduced the Open Agent Safety Platform to help AI developers contain and control AI models, aiming to prevent incidents like OpenAI's July breach. OpenAI has paused the release of its GPT-6.1 Astra model due to safety concerns. Meanwhile, A...
Volatility Shares 2x Ether ETF struggles in choppy markets despite strong Ethereum institutional demand.
The Volatility Shares 2x Ether ETF (ETHU) aims to deliver twice the daily performance of Ethereum but is best suited for smooth, sustained uptrends due to its daily resets, derivatives exposure, and a 2.97% expense ratio. These factors make it unsuit...
SCHD ETF's dividend strategy naturally favors buying after price drops, offering a contrarian edge.
The Schwab U.S. Dividend Equity ETF (SCHD) uses a methodology focused on dividend yield and quality, which tends to favor high-yield stocks after their prices have declined. This approach is not designed for market timing but results in a contrarian ...
Defence Therapeutics appoints Sherry Aulin to Board, boosting expertise in finance and biotech.
Defence Therapeutics, a biotech company focused on precision oncology, has appointed Sherry Aulin to its Board of Directors and Audit Committee. Aulin brings over 20 years of finance experience, including a decade as CFO of Xenon Pharmaceuticals, whe...
Ondine Biomedical partners with NHS to prove Steriwave cuts hospital infections and saves costs fast
Ondine Biomedical has partnered with Mela Solutions, whose software is used in 90% of NHS intensive care units, to help hospitals quickly assess the cost-saving impact of its Steriwave antimicrobial treatment. Steriwave uses light to activate a treat...
Ketamine-based alcohol treatment cuts heavy drinking days by 67%, outperforming some existing drugs in analysis
Solvonis Therapeutics reported that its ketamine-based treatment, SVN-001, reduced heavy drinking days by 67% compared to placebo over four months after treatment, based on a phase II trial analysis. This reduction surpasses results seen with naltrex...
TempraMed signs LOI for exclusive distribution of VIVI Cap™ and VIVI Epi™ in Cyprus with CPO Cyprus.
TempraMed Technologies has signed a non-binding letter of intent with Cyprus Pharmaceutical Organization Ltd. (CPO Cyprus) to appoint them as the exclusive distributor of TempraMed's temperature-sensitive medication products, VIVI Cap™ and VIVI Epi™,...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.